Daniel Braas

University of California, Los Angeles — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index9.9kcitations110works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(29), Sarcoma Diagnosis and Treatment(19), Mitochondrial Function and Pathology(13), Cancer Genomics and Diagnostics(12), RNA modifications and cancer(11)

Publications109 total

Supplementary Figure Legend and Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 1-4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Figure S1-S9, Table S1 from Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress
2023Open Access
Supplementary Figure 10 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 1 - 4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Figure S1-S9, Table S1 from Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress
2023Open Access
Supplementary Figures 6-8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Data from Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress
2023Open Access
Supplementary Figures 1 - 4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure 10 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure Legend and Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 6-8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Data from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure 9 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure 5 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Data from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 6 - 8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 6 - 8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Thomas G. Graeber(22), Heather R. Christofk(20), Michael A. Teitell(7), Jason T. Lee(6), Shili Xu(5), Harvey R. Herschman(5), Johanna ten Hoeve(4), Markus Müschen(4), Nicholas A. Graham(4), Nicolaos Palaskas(3), Antoni Ribas(3), Laurent Vergnes(3), Kym F. Faull(3), Karen Reue(3), Jing Huang(3), Linsey Stiles(3), Utpal Banerjee(3), Lai N. Chan(3), William E. Lowry(3), Siavash K. Kurdistani(3)